Stephen P. Bottomley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen P. Bottomley has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
A. L. Robertson
Department of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Sciences, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia
2 shared publicationsAmy L. Robertson
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
2 shared publications- Anja S. Knaupp
Monash University
2 shared publications - Ashley M. Buckle
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia
2 shared publications Helen M. Saunders
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
2 shared publications- Dimitri Gilis
Computational Biology and Bioinformatics, Université Libre de Bruxelles, Brussels, Belgium
1 shared publication
Latest Publications
- 16 September 2013
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 66 (12) , 1525-1529
Blind Man’s Bluff – Elaboration of Fragment Hits in the Absence of Structure for the Development of Antitrypsin Deficiency Inhibitors
The three pillars of rational drug design from a fragment library are an efficient screen, a robust assay, and atomic-resolution structures of the protein–ligand complexes. However, not all targets are amenable to structure determination by X-ray crystallography or NMR spectroscopy. In particular, targets involved in diseases of protein misfolding are inherently intractable. In the absence of structures, we are blind. However, the lack of structural information need not preclude the use of fragment-based approaches. The use of appropriate NMR techniques can enable us to detect the effects of protein binding on ligand resonances. In our efforts to identify compounds that affect the kinetics of a1-antitrypsin misfolding, we have used saturation transfer difference NMR spectroscopy to detect hits from mixtures of compounds in a fragment library. In the absence of structures, the initial challenge is three-fold: to (1) distinguish between binding sites; (2) evaluate the relative affinities of hits; and (3) advance them to the stage where activity can be detected in biological assays. We largely achieved these aims by the use of Carr–Purcell–Meiboom–Gill NMR competition experiments that detect differential relaxation of the ligand on protein binding.
- 16 September 2013
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 66 (12) , 1525-1529
Blind Man’s Bluff – Elaboration of Fragment Hits in the Absence of Structure for the Development of Antitrypsin Deficiency Inhibitors
The three pillars of rational drug design from a fragment library are an efficient screen, a robust assay, and atomic-resolution structures of the protein–ligand complexes. However, not all targets are amenable to structure determination by X-ray crystallography or NMR spectroscopy. In particular, targets involved in diseases of protein misfolding are inherently intractable. In the absence of structures, we are blind. However, the lack of structural information need not preclude the use of fragment-based approaches. The use of appropriate NMR techniques can enable us to detect the effects of protein binding on ligand resonances. In our efforts to identify compounds that affect the kinetics of a1-antitrypsin misfolding, we have used saturation transfer difference NMR spectroscopy to detect hits from mixtures of compounds in a fragment library. In the absence of structures, the initial challenge is three-fold: to (1) distinguish between binding sites; (2) evaluate the relative affinities of hits; and (3) advance them to the stage where activity can be detected in biological assays. We largely achieved these aims by the use of Carr–Purcell–Meiboom–Gill NMR competition experiments that detect differential relaxation of the ligand on protein binding.
- Open Access
- 22 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e69416
Conformational Behavior and Aggregation of Ataxin-3 in SDS
Spinocerebellar ataxia type 3 (SCA3) is one of nine polyglutamine (polyQ) diseases all characterized by the presence of intraneuronal inclusions that contain aggregated protein. Aggregation of ataxin-3, the causative protein of SCA3, has been well characterized in vitro, with both pathogenic and non-pathogenic length ataxin-3 undergoing fibrillogenesis. However, only ataxin-3 containing an expanded polyQ tract leads to SCA3. Therefore other cellular factors, not present in previous in vitro studies, may modulate aggregation during disease. The interactions between fibrillar species and cell membranes have been characterized in a number of amyloid diseases, including Huntington’s Disease, and these interactions affect aggregation and toxicity. We have characterized the effects of the membrane mimetic sodium dodecyl sulfate (SDS) on ataxin-3 structure and aggregation, to show that both micellar and non-micellar SDS have differing effects on the two stages of ataxin-3 aggregation. We also demonstrate that fibrillar ataxin-3 binds phospholipids, in particular phosphorylated phosphotidylinositols. These results highlight the effect of intracellular factors on the ataxin-3 misfolding landscape and their implications in SCA3 and polyQ diseases in general are discussed.
- 22 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e69416
Open AccessConformational Behavior and Aggregation of Ataxin-3 in SDS
Spinocerebellar ataxia type 3 (SCA3) is one of nine polyglutamine (polyQ) diseases all characterized by the presence of intraneuronal inclusions that contain aggregated protein. Aggregation of ataxin-3, the causative protein of SCA3, has been well characterized in vitro, with both pathogenic and non-pathogenic length ataxin-3 undergoing fibrillogenesis. However, only ataxin-3 containing an expanded polyQ tract leads to SCA3. Therefore other cellular factors, not present in previous in vitro studies, may modulate aggregation during disease. The interactions between fibrillar species and cell membranes have been characterized in a number of amyloid diseases, including Huntington’s Disease, and these interactions affect aggregation and toxicity. We have characterized the effects of the membrane mimetic sodium dodecyl sulfate (SDS) on ataxin-3 structure and aggregation, to show that both micellar and non-micellar SDS have differing effects on the two stages of ataxin-3 aggregation. We also demonstrate that fibrillar ataxin-3 binds phospholipids, in particular phosphorylated phosphotidylinositols. These results highlight the effect of intracellular factors on the ataxin-3 misfolding landscape and their implications in SCA3 and polyQ diseases in general are discussed.
- Open Access
- 29 January 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e54766
The Roles of Helix I and Strand 5A in the Folding, Function and Misfolding of α1-Antitrypsin
α1-Antitrypsin, the archetypal member of the serpin superfamily, is a metastable protein prone to polymerization when exposed to stressors such as elevated temperature, low denaturant concentrations or through the presence of deleterious mutations which, in a physiological context, are often associated with disease. Experimental evidence suggests that α1-Antitrypsin can polymerize via several alternative mechanisms in vitro. In these polymerization mechanisms different parts of the molecule are proposed to undergo conformational change. Both strand 5 and helix I are proposed to adopt different conformations when forming the various polymers, and possess a number of highly conserved residues however their role in the folding and misfolding of α1-Antitrypsin has never been examined. We have therefore created a range of α1Antitypsin variants in order to explore the role of these conserved residues in serpin folding, misfolding, stability and function. Our data suggest that key residues in helix I mediate efficient folding from the folding intermediate and residues in strand 5A ensure native state stability in order to prevent misfolding. Additionally, our data indicate that helix I is involved in the inhibitory process and that both structural elements undergo differing conformational rearrangements during unfolding and misfolding. These findings suggest that the ability of α1-Antitrypsin to adopt different types of polymers under different denaturing conditions may be due to subtle conformational differences in the transiently populated structures adopted prior to the I and M* states.
- 29 January 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e54766
Open AccessThe Roles of Helix I and Strand 5A in the Folding, Function and Misfolding of α1-Antitrypsin
α1-Antitrypsin, the archetypal member of the serpin superfamily, is a metastable protein prone to polymerization when exposed to stressors such as elevated temperature, low denaturant concentrations or through the presence of deleterious mutations which, in a physiological context, are often associated with disease. Experimental evidence suggests that α1-Antitrypsin can polymerize via several alternative mechanisms in vitro. In these polymerization mechanisms different parts of the molecule are proposed to undergo conformational change. Both strand 5 and helix I are proposed to adopt different conformations when forming the various polymers, and possess a number of highly conserved residues however their role in the folding and misfolding of α1-Antitrypsin has never been examined. We have therefore created a range of α1Antitypsin variants in order to explore the role of these conserved residues in serpin folding, misfolding, stability and function. Our data suggest that key residues in helix I mediate efficient folding from the folding intermediate and residues in strand 5A ensure native state stability in order to prevent misfolding. Additionally, our data indicate that helix I is involved in the inhibitory process and that both structural elements undergo differing conformational rearrangements during unfolding and misfolding. These findings suggest that the ability of α1-Antitrypsin to adopt different types of polymers under different denaturing conditions may be due to subtle conformational differences in the transiently populated structures adopted prior to the I and M* states.
- 26 December 2012
- Published by Springer Nature
- Vol. 769, 115-124
Molecular Pathways to Polyglutamine Aggregation
Over 100 human cellular proteins contain a repetitive polyglutamine tract, however, only nine of these proteins are associated with disease. In these proteins, the expanded polyQ tract perturbs the native conformation, resulting in an ordered aggregation process that leads to the formation of amyloid-like fibrils. The misfolding pathway involves the formation of prefibrillar oligomeric structures, which are proposed to be involved in cellular toxicity. Non-polyQ host protein regions modulate the misfolding pathway, suggesting an importance of protein context in aggregation. This chapter describes the current research regarding polyQ misfolding, with emphasis on the species populated during aggregation, suggesting an important role of protein context in modulating the aggregation pathway.
- 26 December 2012
- Published by Springer Nature
- Vol. 769, 115-124
Molecular Pathways to Polyglutamine Aggregation
Over 100 human cellular proteins contain a repetitive polyglutamine tract, however, only nine of these proteins are associated with disease. In these proteins, the expanded polyQ tract perturbs the native conformation, resulting in an ordered aggregation process that leads to the formation of amyloid-like fibrils. The misfolding pathway involves the formation of prefibrillar oligomeric structures, which are proposed to be involved in cellular toxicity. Non-polyQ host protein regions modulate the misfolding pathway, suggesting an importance of protein context in aggregation. This chapter describes the current research regarding polyQ misfolding, with emphasis on the species populated during aggregation, suggesting an important role of protein context in modulating the aggregation pathway.
- 1 November 2011
- Published by Elsevier in Journal of Molecular Biology
- Vol. 413 (4) , 888-898
Structural Change in β-Sheet A of Z α1-Antitrypsin Is Responsible for Accelerated Polymerization and Disease
- 1 November 2011
- Published by Elsevier in Journal of Molecular Biology
- Vol. 413 (4) , 888-898
Structural Change in β-Sheet A of Z α1-Antitrypsin Is Responsible for Accelerated Polymerization and Disease
- Open Access
- 1 October 2011
- Published by Springer Nature in EMBO Reports
- Vol. 12 (10) , 983-984
The structural diversity in α1‐antitrypsin misfolding
The structure of α1-antitrypsin polymers, which cause a devastating disease, is vigorously debated. Here, the state of the field is discussed in view of a paradigm-changing structure published in this issue of EMBO reports.
- 1 October 2011
- Published by Springer Nature in EMBO Reports
- Vol. 12 (10) , 983-984
Open AccessThe structural diversity in α1‐antitrypsin misfolding
The structure of α1-antitrypsin polymers, which cause a devastating disease, is vigorously debated. Here, the state of the field is discussed in view of a paradigm-changing structure published in this issue of EMBO reports.
- Open Access
- 20 July 2011
- Published by Wiley in Protein Science
- Vol. 20 (10) , 1675-1681
Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein
Spinocerebellar Ataxia Type 3 (SCA3) is one of nine polyglutamine (polyQ) diseases that are all characterized by progressive neuronal dysfunction and the presence of neuronal inclusions containing aggregated polyQ protein, suggesting that protein misfolding is a key part of this disease. Ataxin‐3, the causative protein of SCA3, contains a globular, structured N‐terminal domain (the Josephin domain) and a flexible polyQ‐containing C‐terminal tail, the repeat‐length of which modulates pathogenicity. It has been suggested that the fibrillogenesis pathway of ataxin‐3 begins with a non‐polyQ‐dependent step mediated by Josephin domain interactions, followed by a polyQ‐dependent step. To test the involvement of the Josephin domain in ataxin‐3 fibrillogenesis, we have created both pathogenic and nonpathogenic length ataxin‐3 variants with a stabilized Josephin domain, and have both stabilized and destabilized the isolated Josephin domain. We show that changing the thermodynamic stability of the Josephin domain modulates ataxin‐3 fibrillogenesis. These data support the hypothesis that the first stage of ataxin‐3 fibrillogenesis is caused by interactions involving the non‐polyQ containing Josephin domain and that the thermodynamic stability of this domain is linked to the aggregation propensity of ataxin‐3.
- 20 July 2011
- Published by Wiley in Protein Science
- Vol. 20 (10) , 1675-1681
Open AccessFlanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein
Spinocerebellar Ataxia Type 3 (SCA3) is one of nine polyglutamine (polyQ) diseases that are all characterized by progressive neuronal dysfunction and the presence of neuronal inclusions containing aggregated polyQ protein, suggesting that protein misfolding is a key part of this disease. Ataxin‐3, the causative protein of SCA3, contains a globular, structured N‐terminal domain (the Josephin domain) and a flexible polyQ‐containing C‐terminal tail, the repeat‐length of which modulates pathogenicity. It has been suggested that the fibrillogenesis pathway of ataxin‐3 begins with a non‐polyQ‐dependent step mediated by Josephin domain interactions, followed by a polyQ‐dependent step. To test the involvement of the Josephin domain in ataxin‐3 fibrillogenesis, we have created both pathogenic and nonpathogenic length ataxin‐3 variants with a stabilized Josephin domain, and have both stabilized and destabilized the isolated Josephin domain. We show that changing the thermodynamic stability of the Josephin domain modulates ataxin‐3 fibrillogenesis. These data support the hypothesis that the first stage of ataxin‐3 fibrillogenesis is caused by interactions involving the non‐polyQ containing Josephin domain and that the thermodynamic stability of this domain is linked to the aggregation propensity of ataxin‐3.
- 30 May 2011
- Published by Springer Nature
- Vol. 752, 45-57
Refolding Your Protein with a Little Help from REFOLD
The expression and harvesting of proteins from insoluble inclusion bodies by solubilization and refolding is a technique commonly used in the production of recombinant proteins. Despite the importance of refolding, publications in the literature are essentially ad hoc reports consisting of a dazzling array of experimental protocols and a diverse collection of buffer cocktails. For the protein scientists, using this information to refold their protein of interest presents enormous challenges. Here, we describe some of the practical considerations in refolding and present several standard protocols. Further, we describe how refolding procedures can be designed and modified using the information in the REFOLD database (http://refold.med.monash.edu.au), a freely available, open repository for protocols describing the refolding and purification of recombinant proteins.
- 30 May 2011
- Published by Springer Nature
- Vol. 752, 45-57
Refolding Your Protein with a Little Help from REFOLD
The expression and harvesting of proteins from insoluble inclusion bodies by solubilization and refolding is a technique commonly used in the production of recombinant proteins. Despite the importance of refolding, publications in the literature are essentially ad hoc reports consisting of a dazzling array of experimental protocols and a diverse collection of buffer cocktails. For the protein scientists, using this information to refold their protein of interest presents enormous challenges. Here, we describe some of the practical considerations in refolding and present several standard protocols. Further, we describe how refolding procedures can be designed and modified using the information in the REFOLD database (http://refold.med.monash.edu.au), a freely available, open repository for protocols describing the refolding and purification of recombinant proteins.
- Open Access
- 8 November 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 39 (Database) , D272-D276
PolyQ: a database describing the sequence and domain context of polyglutamine repeats in proteins
The polyglutamine diseases are caused in part by a gain-of-function mechanism of neuronal toxicity involving protein conformational changes that result in the formation and deposition of β-sheet rich aggregates. Recent evidence suggests that the misfolding mechanism is context-dependent, and that properties of the host protein, including the domain architecture and location of the repeat tract, can modulate aggregation. In order to allow the bioinformatic investigation of the context of polyglutamines, we have constructed a database, PolyQ (http://pxgrid.med.monash.edu.au/polyq). We have collected the sequences of all human proteins containing runs of seven or more glutamine residues and annotated their sequences with domain information. PolyQ can be interrogated such that the sequence context of polyglutamine repeats in disease and non-disease associated proteins can be investigated.
- 8 November 2010
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 39 (Database) , D272-D276
Open AccessPolyQ: a database describing the sequence and domain context of polyglutamine repeats in proteins
The polyglutamine diseases are caused in part by a gain-of-function mechanism of neuronal toxicity involving protein conformational changes that result in the formation and deposition of β-sheet rich aggregates. Recent evidence suggests that the misfolding mechanism is context-dependent, and that properties of the host protein, including the domain architecture and location of the repeat tract, can modulate aggregation. In order to allow the bioinformatic investigation of the context of polyglutamines, we have constructed a database, PolyQ (http://pxgrid.med.monash.edu.au/polyq). We have collected the sequences of all human proteins containing runs of seven or more glutamine residues and annotated their sequences with domain information. PolyQ can be interrogated such that the sequence context of polyglutamine repeats in disease and non-disease associated proteins can be investigated.
- 15 September 2010
- Published by Elsevier in Journal of Molecular Biology
- Vol. 403 (3) , 459-467
Identification and Characterization of a Misfolded Monomeric Serpin Formed at Physiological Temperature
- 15 September 2010
- Published by Elsevier in Journal of Molecular Biology
- Vol. 403 (3) , 459-467
Identification and Characterization of a Misfolded Monomeric Serpin Formed at Physiological Temperature